Acclarent is a technology company.
Acclarent is a technology company.
Acclarent has raised $86.0M across 3 funding rounds.
Acclarent has raised $86.0M in total across 3 funding rounds.
Acclarent has raised $86.0M in total across 3 funding rounds.
Acclarent's investors include New Enterprise Associates.
Acclarent is a medical technology company specializing in minimally invasive devices for Ear, Nose, and Throat (ENT) conditions. It develops products like balloon sinuplasty systems, navigation technologies, and dilation tools to treat issues such as chronic sinusitis and Eustachian tube dysfunction, serving ENT surgeons and patients worldwide.[1][3][4][5] Acquired by Johnson & Johnson in 2010 and later by Integra LifeSciences in 2024 for $275 million, Acclarent has grown from a venture-backed startup to a leader with over 40 FDA-approved devices, operating in more than 45 countries and employing over 300 people.[3]
Key products include the Relieva Balloon Sinuplasty systems for sinus access, the TruDi Navigation System with AI-powered TruSeg (automatic anatomical segmentation) and TruPath (shortest safe path calculation), and the Aera Eustachian Tube Balloon Dilation System—the first FDA-approved device for Eustachian tube dysfunction.[1][2][3][4] These solve problems like surgical precision, anatomical risks, and chronic ear/nose issues by enabling real-time 3D guidance, reducing trauma, and improving outcomes in procedures like endoscopic sinus surgery.[1][2]
Founded in 2004 by Joshua Makower, who remains Chairman, Acclarent started as a venture-backed company in Irvine, California (later adding Menlo Park headquarters), raising over $103.5 million from investors including New Enterprise Associates, Versant Ventures, and Johnson & Johnson Development Corporation.[3] The idea emerged from a focus on balloon-based innovations for ENT, leading to FDA approval of its flagship Relieva Balloon Sinuplasty technology in May 2005—a minimally invasive alternative to traditional sinus surgery.[3]
Early traction built quickly: by 2010, Johnson & Johnson’s Ethicon Inc. acquired the company, accelerating growth with devices like the Relieva Vortex and Cyclops endoscope.[3] Pivotal moments include the 2017 FDA clearance for the Aera balloon (first for Eustachian tube dysfunction) and the 2021 U.S. launch of AI-enhanced TruDi software, marking leadership in image-guided navigation.[1][2][3][4] Leadership transitioned with Jeff Hopkins as Worldwide President, emphasizing patient-centered innovation.[1][2][3]
Acclarent stands out in ENT medtech through pioneering minimally invasive tools that prioritize precision, safety, and workflow efficiency:
Acclarent rides the wave of AI-augmented surgical navigation and minimally invasive ENT procedures, addressing a market where chronic sinusitis affects millions and precision tools reduce complications like brain/eye damage.[1][2] Timing aligns with rising demand for outpatient ENT interventions post-COVID, as medtech shifts toward AI/ML for real-time feedback—exemplified by TruDi's 2021 launch amid growing endoscopic surgery adoption.[1][2]
Market forces favor it: aging populations drive ENT disorders, while acquisitions (J&J 2010, Integra 2024) provide R&D scale amid consolidation in orthopedics/neurosurgery-adjacent fields.[3] Acclarent influences the ecosystem by setting standards—e.g., balloon dilation expanded treatment options—and enabling surgeons via intuitive tech, fostering broader minimally invasive adoption in a $10B+ ENT device market.[3][4][5]
Acclarent's trajectory points to expanded AI integration in ENT navigation and next-gen balloons for drug delivery or robotics, leveraging Integra's neurosurgery synergies for skull base innovations.[1][3] Trends like AI-driven personalization and ambulatory surgery centers will accelerate growth, potentially doubling procedure volumes as reimbursement improves. Its influence may evolve from pioneer to platform leader, powering ecosystem-wide tools that "free patients to live better lives"—echoing its founding mission amid medtech's precision revolution.[1][5]
Acclarent has raised $86.0M across 3 funding rounds. Most recently, it raised $26.0M Venture Round in January 2009.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2009 | $26.0M Venture Round | New Enterprise Associates | |
| Apr 1, 2007 | $35.0M Series C | New Enterprise Associates | |
| Dec 1, 2005 | $25.0M Series B | New Enterprise Associates |